DUBLIN – (COMMERCIAL THREAD) – The report “Hepatitis C – Competitive landscape in 2021” has been added to ResearchAndMarkets.com offer.
Hepatitis C – Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease market.
In hepatitis C, the non-structural proteins 5A (NS5A) and 5B (NS5B) are major targets of drug developers. There are 138 drugs in the pipeline with 90% molecules present at an early stage of development. Large Pharma dominates R&D in this indication, with Gilead Sciences in the lead. The more frequent use of newer direct-acting antiviral (DAA) therapies is expected to drive the market, but the steady decline in the overall patient base and the high cost of newer DAAs are expected to limit market growth.
This report provides a data-driven overview of the current and future competitive landscape for hepatitis C treatments.
The elements of the report include:
Epidemiology of the disease
Evaluation of marketed drugs
Drug pipeline evaluation
Evaluation of clinical trials
Social media preview
Digital Marketing Overview
Reasons to buy
Develop and design your licensing and licensing strategies by reviewing products and technologies in the pipeline and identifying companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
Generate revenue by understanding key trends, innovative products and technologies, market segments, and companies that may impact the global hepatitis C market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidation, investment and strategic partnership.
Main topics covered:
1.1 Table of contents
1.3 Related reports
1.4 Upcoming related reports
2 Executive summary
2.1 Main findings
2.2 Key events
3.1 Scope of the report
3.2 Disease overview Epidemiological overview
4 Evaluation of marketed drugs
4.1 Overview of marketed drugs
4.2 Profiles of drugs on the market
5 Pipeline assessment
5.1 Pipeline overview
5.2 Distribution of the pipeline by region
5.3 Distribution of the pipeline by molecule type and target
5.4 Drug review designations
5.5 Phase transition success rate
5.6 Likelihood of approval
6 Evaluation of clinical trials
6.1 Overview of clinical trials by phase
6.2 Overview by region
6.4 Perspective of the therapy area
6.4 Main sponsors
6.5 Analysis of registrations
6.6 Feasibility analysis
7 Business evaluation
7.1 Upcoming market catalysts
8 Social media and digital marketing
8.1 Chatter Twitter Key
8.2 Top brands’ websites
8.3 Trust flow and citation flow
For more information on this report, visit https://www.researchandmarkets.com/r/auc2pi